X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1452) 1452
index medicus (1428) 1428
male (900) 900
colitis - chemically induced (898) 898
trinitrobenzenesulfonic acid (799) 799
rats (778) 778
mice (685) 685
disease models, animal (627) 627
colitis (603) 603
inflammatory-bowel-disease (499) 499
colitis - pathology (494) 494
inflammatory bowel disease (433) 433
colitis - drug therapy (422) 422
female (409) 409
colon - pathology (407) 407
gastroenterology & hepatology (405) 405
ulcerative-colitis (397) 397
inflammation (387) 387
rats, wistar (359) 359
crohns-disease (354) 354
colitis - metabolism (352) 352
rats, sprague-dawley (334) 334
colon - drug effects (327) 327
pharmacology & pharmacy (315) 315
trinitrobenzenesulfonic acid - toxicity (314) 314
humans (289) 289
colon - metabolism (283) 283
mice, inbred balb c (277) 277
peroxidase - metabolism (276) 276
abridged index medicus (249) 249
colon (226) 226
colitis - immunology (225) 225
expression (217) 217
rodents (204) 204
intestinal mucosa - pathology (198) 198
immunology (197) 197
mice, inbred c57bl (192) 192
analysis (173) 173
colitis - prevention & control (173) 173
cytokines (170) 170
model (170) 170
inflammatory bowel diseases (166) 166
experimental colitis (160) 160
bowel-disease (156) 156
gastrointestinal diseases (155) 155
intestinal mucosa - metabolism (151) 151
intestinal inflammation (147) 147
colitis - physiopathology (142) 142
intestinal mucosa - drug effects (142) 142
cytokines - metabolism (141) 141
trinitrobenzenesulfonic acid - pharmacology (137) 137
cells (135) 135
ulcerative colitis (135) 135
tumor necrosis factor-alpha - metabolism (129) 129
anti-inflammatory agents - pharmacology (125) 125
time factors (119) 119
inflammatory bowel-disease (114) 114
nf-kappa-b (111) 111
trinitrobenzenesulfonic acid - adverse effects (109) 109
colitis, ulcerative - chemically induced (108) 108
trinitrobenzenesulfonic acid - administration & dosage (108) 108
activation (107) 107
gastroenterology (107) 107
research (106) 106
dose-response relationship, drug (105) 105
immunohistochemistry (104) 104
tnbs (102) 102
physiology (101) 101
inhibition (100) 100
intestine (100) 100
nf-kappa b - metabolism (100) 100
cells, cultured (99) 99
mice, knockout (98) 98
anti-inflammatory agents - therapeutic use (97) 97
biochemistry & molecular biology (96) 96
rat (96) 96
crohn's disease (95) 95
colon - immunology (93) 93
gene expression (90) 90
tnbs-induced colitis (90) 90
apoptosis (89) 89
oxidative stress (89) 89
administration, oral (86) 86
health aspects (86) 86
medicine & public health (86) 86
medicine, research & experimental (86) 86
physiological aspects (86) 86
pathogenesis (85) 85
inflammatory bowel diseases - chemically induced (82) 82
neurosciences (80) 80
colitis, ulcerative - drug therapy (79) 79
oncology (79) 79
tumor-necrosis-factor (79) 79
article (78) 78
colitis - therapy (78) 78
inflammatory bowel diseases - pathology (78) 78
cell biology (76) 76
research article (76) 76
colitis - genetics (75) 75
enzyme-linked immunosorbent assay (75) 75
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1468) 1468
Chinese (12) 12
Japanese (4) 4
Russian (2) 2
French (1) 1
German (1) 1
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Molecules, ISSN 1420-3049, 06/2017, Volume 22, Issue 6, p. 904
Drugs such as mesalamine (5-ASA) are currently recommended for the treatment of inflammatory bowel disease (IBD). To reduce the frequency of their... 
Inflammatory bowel disease | Remission | Mucosal healing | Colitis | Hyaluronic acid | ACTIVATION | colitis | ANGIOGENESIS | INVOLVEMENT | CHEMISTRY, ORGANIC | INTERLEUKIN-6 | inflammatory bowel disease | hyaluronic acid | TELMISARTAN | DEGRADATION-PRODUCTS | remission | PPAR-GAMMA | EXPRESSION | CD44 | mucosal healing | TNBS-INDUCED COLITIS | Inflammatory Bowel Diseases - drug therapy | Intestinal Mucosa - metabolism | Cytokines - metabolism | Trinitrobenzenesulfonic Acid - administration & dosage | Rats | Hyaluronic Acid - pharmacology | Male | Inflammatory Bowel Diseases - metabolism | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Trinitrobenzenesulfonic Acid - adverse effects | Mesalamine - pharmacology | Animals | Protective Agents - pharmacology | Inflammatory Bowel Diseases - pathology | Cyclooxygenase 2 - metabolism | Inflammation Mediators - metabolism | Inflammatory Bowel Diseases - chemically induced | Disease Models, Animal | Intestinal Mucosa - pathology | Peroxidase - metabolism | Inflammatory bowel diseases | Wound healing | Mucosa | Medical treatment | Prostaglandin endoperoxide synthase | Injury prevention | Acids | Intestine | Ulcers | Rodents | Animal tissues | Vascular tissue | Peroxidase | Combined treatment | Colon | Cyclooxygenase-2 | Injuries | Index Medicus
Journal Article
Naunyn-Schmiedeberg's Archives of Pharmacology, ISSN 0028-1298, 6/2015, Volume 388, Issue 6, pp. 643 - 651
Journal Article
International Immunopharmacology, ISSN 1567-5769, 02/2013, Volume 15, Issue 2, pp. 372 - 380
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 197, pp. 48 - 57
Journal Article
Journal Article
Journal of Immunology, ISSN 0022-1767, 07/2017, Volume 199, Issue 2, pp. 718 - 733
GPBAR1 (TGR5 or M-BAR) is a G protein-coupled receptor for secondary bile acids that is highly expressed in monocytes/ macrophages. In this study, we aimed to... 
IMMUNITY | HOMEOSTASIS | DENDRITIC CELLS | INTEGRINS | FARNESOID X RECEPTOR | INFLAMMATION | CHEMOKINES | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | THERAPEUTIC TARGETS | MICROBIOTA | IMMUNOLOGY | Receptors, G-Protein-Coupled - metabolism | Chemokine CCL2 - immunology | Tumor Necrosis Factor-alpha - genetics | Antigens, Ly - genetics | Interleukin-1beta - genetics | Receptors, G-Protein-Coupled - agonists | T-Lymphocytes, Regulatory - immunology | Intestinal Mucosa - immunology | Colitis - chemically induced | Tumor Necrosis Factor-alpha - immunology | Colitis - immunology | Macrophages - immunology | Cell Line | Promoter Regions, Genetic | Interleukin-10 - deficiency | Interleukin-6 - genetics | Gene Expression Regulation - immunology | Trinitrobenzenesulfonic Acid - administration & dosage | Interleukin-1beta - immunology | Chemokine CCL2 - genetics | Inflammation - immunology | Macrophage Activation | Cholestanols - pharmacology | Phenotype | T-Lymphocytes, Regulatory - drug effects | Animals | Receptors, G-Protein-Coupled - deficiency | Antigens, Ly - immunology | Mucous Membrane - immunology | Interleukin-10 - genetics | Colitis - metabolism | Interleukin-6 - immunology | Macrophages - drug effects | Mice | Oxazolone - administration & dosage | Receptors, G-Protein-Coupled - genetics | Interleukin-10 - immunology | Cell Movement | Cholestanols - administration & dosage | CC chemokine receptors | Oxazolone | Animal models | Inflammatory bowel diseases | Trafficking | Mucosa | Activation | Regulatory sequences | Macrophages | Recruitment | Interleukin 6 | Genotype & phenotype | Cell activation | Intestine | Foxp3 protein | Colon | CD11b antigen | Bile acids | CCR7 protein | Lamina propria | Exposure | Cyclic AMP response element-binding protein | Gene expression | Ablation | CD4 antigen | Inflammatory bowel disease | White blood cells | Monocytes | Acids | Tumor necrosis factor | γ-Interferon | Interleukin 10 | Interferon | Colitis | Monocyte chemoattractant protein 1 | Bile | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 01/2013, Volume 698, Issue 1-3, pp. 404 - 412
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2017, Volume 174, Issue 15, pp. 2501 - 2511
BACKGROUND AND PURPOSE Defective autophagy contributes to the pathogenesis of inflammatory disorders such as inflammatory bowel disease and there are... 
PATHWAYS | APOPTOSIS | ACTIVATION | EPITHELIAL-CELLS | LYSOSOMAL DEGRADATION | GUIDELINES | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | SELECTIVE AUTOPHAGY | NEMO | BOWEL-DISEASE | Betacyanins - administration & dosage | Intestinal Mucosa - metabolism | Trinitrobenzenesulfonic Acid - administration & dosage | Injections, Intraperitoneal | Administration, Rectal | Colitis - pathology | Male | Sirolimus - pharmacology | Autophagy - drug effects | Intestinal Mucosa - drug effects | Sirolimus - administration & dosage | Inflammation - metabolism | Animals | Inflammation - drug therapy | Colitis - chemically induced | Betacyanins - pharmacology | Female | Colitis - drug therapy | Mice | Mice, Inbred BALB C | Trehalose - administration & dosage | Trehalose - pharmacology | Prevention | Inflammation | Colitis | RNA | Gastrointestinal diseases | TOR protein | CC chemokine receptors | Drinking water | Inflammatory bowel diseases | Trehalose | CD86 antigen | Mucosa | Body weight | Body weight loss | Macrophages | Autophagy | Inflammatory diseases | Western blotting | Interleukin 6 | Proteins | Intestine | Rodents | Interleukin 1 | CD11c antigen | CCR7 protein | Rapamycin | Gene expression | Nitric-oxide synthase | Inflammatory bowel disease | Polymerase chain reaction | Interleukin 10 | Bcl-10 protein | Cyclooxygenase-2 | Phagocytosis | Index Medicus | Research Papers | Research Paper
Journal Article